Trials / Active Not Recruiting
Active Not RecruitingNCT06717438
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPN14770 | Capsules for oral administration |
| DRUG | Placebo | Capsules for oral administration |
Timeline
- Start date
- 2025-05-13
- Primary completion
- 2030-01-31
- Completion
- 2030-01-31
- First posted
- 2024-12-05
- Last updated
- 2026-01-20
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06717438. Inclusion in this directory is not an endorsement.